SPP1-positive Myeloid Cell Subpopulations Associated with Resistance to PD-1/L1 Immunotherapy in Non-small Cell Lung Cancer

NIAID Data Ecosystem2026-05-02 收录

非小细胞肺癌免疫治疗

肿瘤微环境单细胞解析

数据链接：

https://www.ncbi.nlm.nih.gov/sra/SRP610177 数据链接链接失效反馈

官方服务：

资源简介：

NSCLC patients Fresh tumor tissues from three patients per group underwent single-cell RNA sequencing (scRNA-seq), and one sample per group was analyzed using spatial transcriptomics

创建时间：

2025-08-22

HiTIMED: hierarchical tumor immune microenvironment epigenetic deconvolution for accurate cell type resolution in the tumor microenvironment using tumor‑type‑specific DNA methylation data. HiTIMED: hierarchical tumor immune microenvironment epigenetic deconvolution for accurate cell type resolution in the tumor microenvironment using tumor‑type‑specific DNA methylation data

肿瘤微环境单细胞解析

DNA甲基化

The solid tumor microenvironment is heterogeneous and varies in composition by tumor type. High-resolution profiling of the cell composition in tumor microenvironments is crucial to understanding its

NIAID Data Ecosystem80

DataSheet_1_Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management.docx

免疫检查点抑制剂肺炎

非小细胞肺癌免疫治疗

Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death- ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has revolutionized the therapeutic strategy

NIAID Data Ecosystem20

Dataset from An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

非小细胞肺癌免疫治疗

临床试验生存分析

The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared w

NIAID Data Ecosystem10

Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy

癌症免疫治疗响应预测

肿瘤微环境单细胞解析

Despite the acknowledged effectiveness of BCMA chimeric antigen receptor T (CAR-T) cells in killing multiple myeloma (MM) cells, predicting treatment responsivity to BCMA CAR-T therapy remains a chall

NIAID Data Ecosystem70

ATAD2 is a Potential Immunotherapy Target for Patients with Small Cell Lung Cancer Harboring HLA-A*0201

非小细胞肺癌免疫治疗

HLA抗原呈递

To identify the immune peptides in SCLC tumour cells that can be processed and presented by HLA-I, we performed LC–MS/MS analysis on 11 SCLC cell lines, representing the heterogeneity of SCLC subtypes

国家人口健康科学数据中心10

SPP1-positive Myeloid Cell Subpopulations Associated with Resistance to PD-1/L1 Immunotherapy in Non-small Cell Lung Cancer

资源简介：

相关数据集